Johnson & Johnson (NYSE:JNJ) Position Raised by Purkiss Capital Advisors LLC

Purkiss Capital Advisors LLC grew its stake in Johnson & Johnson (NYSE:JNJ) by 7.6% during the 1st quarter, HoldingsChannel reports. The firm owned 13,679 shares of the company’s stock after buying an additional 964 shares during the quarter. Johnson & Johnson accounts for about 1.7% of Purkiss Capital Advisors LLC’s investment portfolio, making the stock its 9th biggest holding. Purkiss Capital Advisors LLC’s holdings in Johnson & Johnson were worth $2,269,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in the business. Lantz Financial LLC raised its stake in Johnson & Johnson by 3.3% in the 1st quarter. Lantz Financial LLC now owns 11,974 shares of the company’s stock valued at $1,986,000 after purchasing an additional 377 shares during the last quarter. Sulzberger Capital Advisors Inc. acquired a new position in Johnson & Johnson in the 4th quarter valued at $453,000. Joel Isaacson & Co. LLC raised its stake in Johnson & Johnson by 3.5% in the 1st quarter. Joel Isaacson & Co. LLC now owns 74,132 shares of the company’s stock valued at $12,294,000 after purchasing an additional 2,526 shares during the last quarter. State of Wyoming raised its stake in Johnson & Johnson by 205,580.0% in the 4th quarter. State of Wyoming now owns 10,284 shares of the company’s stock valued at $1,487,000 after purchasing an additional 10,279 shares during the last quarter. Finally, Range Financial Group LLC raised its stake in Johnson & Johnson by 18.9% in the 1st quarter. Range Financial Group LLC now owns 15,886 shares of the company’s stock valued at $2,635,000 after purchasing an additional 2,529 shares during the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms recently commented on JNJ. Morgan Stanley increased their price objective on Johnson & Johnson from $171.00 to $176.00 and gave the company an “equal weight” rating in a research note on Thursday, July 17th. Leerink Partnrs downgraded Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, May 13th. Piper Sandler reaffirmed an “overweight” rating on shares of Johnson & Johnson in a research note on Thursday, July 17th. Erste Group Bank raised Johnson & Johnson from a “hold” rating to a “buy” rating in a research note on Wednesday, July 23rd. Finally, Royal Bank Of Canada raised their target price on Johnson & Johnson from $181.00 to $185.00 and gave the stock an “outperform” rating in a research note on Thursday, July 17th. Nine investment analysts have rated the stock with a hold rating, ten have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $174.50.

Johnson & Johnson Stock Performance

NYSE JNJ opened at $168.29 on Monday. The stock has a fifty day simple moving average of $156.08 and a 200-day simple moving average of $155.97. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $169.99. The stock has a market cap of $404.92 billion, a PE ratio of 18.00, a P/E/G ratio of 2.14 and a beta of 0.41. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, beating analysts’ consensus estimates of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%. The company had revenue of $23.74 billion during the quarter, compared to analysts’ expectations of $22.85 billion. During the same period last year, the business posted $2.82 EPS. Johnson & Johnson’s revenue for the quarter was up 5.8% on a year-over-year basis. Equities analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th will be issued a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 3.09%. The ex-dividend date is Tuesday, August 26th. Johnson & Johnson’s dividend payout ratio (DPR) is 55.61%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.